Cargando…

Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population

BACKGROUND: Severe alpha-1-antitrypsin deficiency (AATD) is an established risk factor for chronic obstructive pulmonary disease (COPD) and liver disease, but the effect on the incidence of ischemic heart disease (IHD) is not well known. The aim was to evaluate the risk of incident IHD in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanash, Hanan, Ekström, Magnus, Basil, Nawfal, Rönmark, Eva, Lindberg, Anne, Piitulainen, Eeva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282800/ https://www.ncbi.nlm.nih.gov/pubmed/32606637 http://dx.doi.org/10.2147/COPD.S247377

Ejemplares similares

Survival in severe alpha-1-antitrypsin deficiency (PiZZ)
por: Tanash, Hanan A, et al.
Publicado: (2010)

Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden
por: Tanash, Hanan A, et al.
Publicado: (2016)

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
por: Schmid, ST, et al.
Publicado: (2012)

Liver disease in adults with severe alpha-1-antitrypsin deficiency
por: Tanash, Hanan A., et al.
Publicado: (2019)

The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening
por: Hiller, Adriana-Maria, et al.
Publicado: (2022)

Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43–45 years
por: Mostafavi, Behrouz, et al.
Publicado: (2019)

Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency
por: Esquinas, Cristina, et al.
Publicado: (2017)

Prevalence of α(1)-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review
por: Blanco, Ignacio, et al.
Publicado: (2020)

Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age
por: Mostafavi, Behrouz, et al.
Publicado: (2017)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37–40 years
por: Piitulainen, Eeva, et al.
Publicado: (2017)

Acoustic radiation force impulse (ARFI) elastography in a cohort of alpha-1 antitrypsin-deficient individuals and healthy volunteers
por: Diaz, Sandra, et al.
Publicado: (2018)

Fibrosis-Related Gene Profiling in Liver Biopsies of PiZZ α1-Antitrypsin Children with Different Clinical Courses
por: Kamp, Jan C., et al.
Publicado: (2023)

Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42
por: Schramm, Georg Rüdiger, et al.
Publicado: (2021)

Lung transplantation and survival outcomes in patients with oxygen-dependent COPD with regard to their alpha-1 antitrypsin deficiency status
por: Ekström, Magnus, et al.
Publicado: (2017)

Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency
por: Mostafavi, Behrouz, et al.
Publicado: (2018)

Low Prevalence of Mild Alpha-1-Antitrypsin Deficiency in Hospitalized COVID-19-Patients
por: Nygren, David, et al.
Publicado: (2022)

Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update
por: Blanco, Ignacio, et al.
Publicado: (2017)

The prevalence of liver abnormalities in individuals with ZZ Alpha-1 Antitrypsin deficiency
por: McElvaney, OF, et al.
Publicado: (2015)

Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals
por: Sandström, Caroline S, et al.
Publicado: (2008)

The Relationship between Plasma Alpha-1-Antitrypsin Polymers and Lung or Liver Function in ZZ Alpha-1-Antitrypsin-Deficient Patients
por: Sark, Annelot D., et al.
Publicado: (2022)

Hypoxia Enhances Oxidative Stress in Neutrophils from ZZ Alpha-1 Antitrypsin Deficiency Patients
por: Magallón, María, et al.
Publicado: (2023)

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency
por: Parr, David G, et al.
Publicado: (2009)

Demographic and clinical characteristics of patients with α(1)-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO
por: Torres-Durán, María, et al.
Publicado: (2022)

Intrahepatic cholangiocarcinoma in a non-cirrhotic liver in a patient with homozygous ZZ alpha-1 antitrypsin deficiency
por: Vuurberg, Nienke E, et al.
Publicado: (2021)

Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?
por: McGee, Dawn, et al.
Publicado: (2010)

Plasma levels of alpha1-antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe α1-antitrypsin deficiency
por: Hollander, Camilla, et al.
Publicado: (2007)

Prevalence of PI*Z and PI*S alleles of alpha-1-antitrypsin deficiency in Finland
por: Häggblom, Jan, et al.
Publicado: (2015)

Refractory Classical Hodgkin Lymphoma Presenting with Atypical Cutaneous Involvement and Diagnosis of ZZ Phenotype Alpha-1 Antitrypsin Deficiency
por: Khawandanah, Mohamad, et al.
Publicado: (2014)

Diffuse panniculitis in a teenage male with ZZ α(1)-antitrypsin deficiency
por: Papiris, Spyros A., et al.
Publicado: (2023)

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration
por: Parr, David G., et al.
Publicado: (2022)

Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry
por: Stockley, Robert A, et al.
Publicado: (2010)

Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency
por: Mayer, Annyce S, et al.
Publicado: (2006)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2022)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

COPD in individuals with the PiMZ alpha-1 antitrypsin genotype
por: Al Ashry, Haitham S., et al.
Publicado: (2017)

The risk of burn injury during long-term oxygen therapy: a 17-year longitudinal national study in Sweden
por: Tanash, Hanan A, et al.
Publicado: (2015)

Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i8kgnb21pklmktgu3udirfp65g